Trastuzumab deruxtecan is already approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of HER2-positive metastatic BC that has already been treated with two or more lines of anti-HER2-based therapies (Gampenrieder et al. 2021). This evidence concerns the gene ERBB2 and breast cancer.